Results showed a significant benefit in patients with stage II-IIIA and PD-L1 ≥ 1%, as assessed by the Ventana (SP263) assay, and in all patients with stage II-IIIA NSCLC, irrespective of PD-L1 expression. The gene discussed is CD274; the disease is non-small cell lung carcinoma.